41 related articles for article (PubMed ID: 31851430)
1. Improving practice in PD-L1 testing of non-small cell lung cancer in the UK: current problems and potential solutions.
Gosney JR; Peake MD; Kerr KM
J Clin Pathol; 2024 Jan; 77(2):135-139. PubMed ID: 36604178
[TBL] [Abstract][Full Text] [Related]
2. Accuracy of Cytologic vs Histologic Specimens for Assessment of Programmed Cell Death Ligand-1 Expression in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Tajarernmuang P; Aliaga F; Alwakeel AJ; Tavaziva G; Turner K; Menzies D; Wang H; Ofiara L; Benedetti A; Gonzalez AV
Chest; 2024 Feb; 165(2):461-474. PubMed ID: 37739030
[TBL] [Abstract][Full Text] [Related]
3. Effect of Fixatives and Fixation Period on Morphology and Immunohistochemistry of Feline Ovarian Tissue.
Alkali IM; Colombo M; Rodak O; Nizanski W; Luvoni GC
Animals (Basel); 2024 Mar; 14(6):. PubMed ID: 38539923
[TBL] [Abstract][Full Text] [Related]
4. Comparison of histological procedures and antigenicity of human post-mortem brains fixed with solutions used in gross anatomy laboratories.
Frigon EM; Gérin-Lajoie A; Dadar M; Boire D; Maranzano J
Front Neuroanat; 2024; 18():1372953. PubMed ID: 38659652
[TBL] [Abstract][Full Text] [Related]
5. EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.
Jug R; Giovacchini CX; Liu B; Green CL; Clarke JM; Mahmood K; Pavlisko EN
J Am Soc Cytopathol; 2020; 9(6):485-493. PubMed ID: 32336671
[TBL] [Abstract][Full Text] [Related]
6. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for PD-L1 Testing in Non-small Cell Lung Cancer.
Perrotta F; Nankivell M; Adizie JB; Maqsood U; Elshafi M; Jafri S; Lerner AD; Woolhouse I; Munavvar M; Evison M; Booton R; Baldwin DR; Janes SM; Kerr KM; Bianco A; Yarmus L; Navani N
Chest; 2020 Sep; 158(3):1230-1239. PubMed ID: 32428509
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic yield of endobronchial ultrasound-guided transbronchial needle aspiration to assess tumor-programmed cell death ligand-1 expression in mediastinal lymph nodes metastasized from non-small cell lung cancer.
Mineura K; Hamaji M; Yoshizawa A; Nakajima N; Kayawake H; Tanaka S; Yamada Y; Yutaka Y; Nakajima D; Ohsumi A; Menju T; Chen-Yoshikawa TF; Date H
Surg Today; 2020 Sep; 50(9):1049-1055. PubMed ID: 32166496
[TBL] [Abstract][Full Text] [Related]
8. Is it necessary to sample the contralateral nodal stations by EBUS-TBNA in patients with lung cancer and clinical N0 / N1 on PET-CT?
Serra P; Centeno C; Sanz-Santos J; Torky M; Baeza S; Mendiluce L; Martínez-Barenys C; López de Castro P; Abad J; Rosell A; Andreo F
Lung Cancer; 2020 Apr; 142():9-12. PubMed ID: 32062200
[TBL] [Abstract][Full Text] [Related]
9. Nationwide differences in cytology fixation and processing methods and their impact on interlaboratory variation in PD-L1 positivity.
Koomen BM; de Boer M; van Dooijeweert C; van Lindert ASR; Deckers IAG; Voorham QJM; Willems SM
Virchows Arch; 2023 Apr; 482(4):707-720. PubMed ID: 36370167
[TBL] [Abstract][Full Text] [Related]
10. Program death ligand-1 immunocytochemistry in lung cancer cytological samples: A systematic review.
Satturwar S; Girolami I; Munari E; Ciompi F; Eccher A; Pantanowitz L
Diagn Cytopathol; 2022 Jun; 50(6):313-323. PubMed ID: 35293692
[TBL] [Abstract][Full Text] [Related]
11. Linear Endobronchial Ultrasound in the Era of Personalized Lung Cancer Diagnostics-A Technical Review.
Oezkan F; Eisenmann S; Darwiche K; Gassa A; Carbone DP; Merritt RE; Kneuertz PJ
J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884348
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 Testing in Cytological Non-Small Cell Lung Cancer Specimens: A Comparison with Biopsies and Review of the Literature.
Mansour MSI; Lindquist KE; Seidal T; Mager U; Mohlin R; Tran L; Hejny K; Holmgren B; Violidaki D; Dobra K; Dejmek A; Planck M; Brunnström H
Acta Cytol; 2021; 65(6):501-509. PubMed ID: 34233336
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 and beyond: Immuno-oncology in cytopathology.
Iaccarino A; Salatiello M; Migliatico I; De Luca C; Gragnano G; Russo M; Bellevicine C; Malapelle U; Troncone G; Vigliar E
Cytopathology; 2021 Sep; 32(5):596-603. PubMed ID: 33955097
[TBL] [Abstract][Full Text] [Related]
14. Implementation of PD-L1 22C3 IHC pharmDxTM in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation.
Lou SK; Ko HM; Kinoshita T; MacDonald S; Weiss J; Czarnecka-Kujawa K; Boerner SL; Yasufuku K; Tsao MS; Schwock J
Acta Cytol; 2020; 64(6):577-587. PubMed ID: 32599583
[TBL] [Abstract][Full Text] [Related]
15. Programmed death ligand 1 expression in EBUS aspirates of non-small cell lung cancer: Is interpretation affected by type of fixation?
Gosney JR; Haragan A; Chadwick C; Giles TE; Grundy S; Tippett V; Gumparthy KP; Wight A; Tan HG
Cancer Cytopathol; 2020 Feb; 128(2):100-106. PubMed ID: 31851430
[TBL] [Abstract][Full Text] [Related]
16. False-negative programmed death-ligand 1 immunostaining in ethanol-fixed endobronchial ultrasound-guided transbronchial needle aspiration specimens of non-small-cell lung cancer patients.
Koomen BM; Vreuls W; de Boer M; de Ruiter EJ; Hoelters J; Vink A; Willems SM
Histopathology; 2021 Oct; 79(4):480-490. PubMed ID: 33772818
[TBL] [Abstract][Full Text] [Related]
17. Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer.
Koomen BM; van der Starre-Gaal J; Vonk JM; von der Thüsen JH; van der Meij JJC; Monkhorst K; Willems SM; Timens W; 't Hart NA
Cancer Cytopathol; 2021 Apr; 129(4):304-317. PubMed ID: 33108706
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
